These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34022222)

  • 1. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
    Kamm DR; Pyles KD; Sharpe MC; Healy LN; Colca JR; McCommis KS
    J Biol Chem; 2021; 296():100807. PubMed ID: 34022222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
    J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
    Colca JR; McDonald WG; Adams WJ
    Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
    Benova A; Ferencakova M; Bardova K; Funda J; Prochazka J; Spoutil F; Cajka T; Dzubanova M; Balcaen T; Kerckhofs G; Willekens W; van Lenthe GH; Alquicer G; Pecinova A; Mracek T; Horakova O; Rossmeisl M; Kopecky J; Tencerova M
    Mol Metab; 2022 Nov; 65():101598. PubMed ID: 36103974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
    Liu Q; Cai BY; Zhu LX; Xin X; Wang X; An ZM; Li S; Hu YY; Feng Q
    Life Sci; 2020 Nov; 261():118457. PubMed ID: 32961235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
    Ferguson D; Eichler SJ; Yiew NKH; Colca JR; Cho K; Patti GJ; Shew TM; Lutkewitte AJ; Mukherjee S; McCommis KS; Niemi NM; Finck BN
    Mol Metab; 2023 Apr; 70():101694. PubMed ID: 36801448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
    Larsen PJ; Wulff EM; Gotfredsen CF; Brand CL; Sturis J; Vrang N; Knudsen LB; Lykkegaard K
    Diabetes Obes Metab; 2008 Apr; 10(4):301-11. PubMed ID: 18333889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
    Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].
    Song LL; Xiao JZ; Yang WY; Zhang M; Liu BB; Pan L
    Zhonghua Nei Ke Za Zhi; 2011 Sep; 50(9):781-4. PubMed ID: 22176969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
    McCommis KS; Hodges WT; Brunt EM; Nalbantoglu I; McDonald WG; Holley C; Fujiwara H; Schaffer JE; Colca JR; Finck BN
    Hepatology; 2017 May; 65(5):1543-1556. PubMed ID: 28027586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
    Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
    Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
    Yamamoto S; Hayashi T; Ohara M; Goto S; Sato J; Nagaike H; Fukase A; Sato N; Hiromura M; Tomoyasu M; Nakanishi N; Lee S; Osamura A; Yamamoto T; Fukui T; Hirano T
    Diabetes Res Clin Pract; 2018 Jun; 140():339-346. PubMed ID: 29588170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
    Elkind-Hirsch KE; Shaler D; Harris R
    J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.